
[EPISODE 20] Dr. David Johnson Talks Frosted Flakes, Small Molecules, and Pharmacokinetics!
On this episode of Molecular Moments, Dr. Jim McNally chats with DMPK Senior Director Dr. David Johnson, Ph.D., from BioAgilytix
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
34,000 Square Feet
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
78,685 Square Feet
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
26,453 Square Feet
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
2,777 Square Meters
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Dr. Jim McNally chats with DMPK Senior Director Dr. David Johnson, Ph.D., from BioAgilytix
Cell-based assays are an important tool in drug development. One of the biggest challenges when developing a drug is mimicking the
Summary In an article published by Pharmaceutical Technology Europe, BioAgilytix BioAgilytix supplies its assay expertise to describe the appropriate analytical
Summary In an Expert Opinion article published by Contract Pharma, PD Dr. Arno Kromminga of BioAgilytix discusses testing challenges and
Durham, NC, July 21, 2022 – BioAgilytix Labs, LLC (BioAgilytix) has secured a valuable seal of approval for the safety of
Durham, NC, June 30, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical
Cell-based assays are an important tool in drug development. One of the biggest challenges when developing a drug is mimicking the
ADCC Antibody dependent cellular cytotoxicity (ADCC) is a mechanism in host immune defense where antibodies bind to an antigen on
Gene editing isn’t a new concept and has been around for decades. In its infancy, gene editing was time-consuming, inaccurate
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
34,000 Square Feet
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
78,685 Square Feet
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
26,453 Square Feet
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
2,777 Square Meters
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Dr. Jim McNally chats with DMPK Senior Director Dr. David Johnson, Ph.D., from BioAgilytix
Cell-based assays are an important tool in drug development. One of the biggest challenges when developing a drug is mimicking the
Summary In an article published by Pharmaceutical Technology Europe, BioAgilytix BioAgilytix supplies its assay expertise to describe the appropriate analytical
Summary In an Expert Opinion article published by Contract Pharma, PD Dr. Arno Kromminga of BioAgilytix discusses testing challenges and
Durham, NC, July 21, 2022 – BioAgilytix Labs, LLC (BioAgilytix) has secured a valuable seal of approval for the safety of
Durham, NC, June 30, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical
Cell-based assays are an important tool in drug development. One of the biggest challenges when developing a drug is mimicking the
ADCC Antibody dependent cellular cytotoxicity (ADCC) is a mechanism in host immune defense where antibodies bind to an antigen on
Gene editing isn’t a new concept and has been around for decades. In its infancy, gene editing was time-consuming, inaccurate
For Qualitative Analysis of Cellular Immune Responses
BioAgilytix offers Enzyme-Linked ImmunoSpot (ELISpot) assays at our European laboratory in Hamburg, Germany. Qualified and validated for regulated work, BioAgilytix’s ELISpot platform provides robust data on cell-mediated immunity for regulated immune monitoring studies for biologics, Cell and Gene Clinical Development Support.
Our passion for the science of small and large molecule bioanalysis drives our ability to deliver premium, tailored services for biomarker, immunogenicity, pharmacokinetics (PK), and cell-based assays.
The ELISpot platform is considered among the most useful for determining cell-mediated immunity because of its sensitivity and specificity in detecting rare antigen-specific T cells (or B cells). ELISpot assays are able to provide qualitative information regarding the specific cytokine or other secreted immune molecule.
We use ELISpot to visualize the secretory product(s) of individual activated or responding cells to analyze the frequencies of rare antigen-specific cells within a test population, such as single positive cells within a population of peripheral blood mononuclear cells (PBMCs).
At BioAgilytix, we most frequently utilize ELISpot in our work with Cytotoxic T Cell Response, Helper T Cell Response, B Cell Antibody response, Epitope Discovery, immune response monitoring, epitope discovery, and helper T cell response evaluation. Specific to bioanalytical assessment of cell and gene therapies, ELISpot can be used to assess cellular immune responses against the vector. We can also use fluorescently labeled antibodies, even in parallel via multiplexing.
ELISpot offers exceptional sensitivity for the detection and enumeration of rare antigen-specific cells because of its method of capturing and secreting cytokine, which overcomes some of the limitations of the traditional ELISA method. ELISpot allows for detection of a single cell that secrets a protein of interest (cytokine, effector protein, receptor, surface marker, antibody) – and since the cytokine released in response to antigen can be mapped to a single cell, T cell responder frequencies can be calculated.
It also provides an indication of the type of cytokine response that has been elicited and hence the type of immune response. As such, ELISpot assays are able to provide high-quality qualitative information regarding the specific cytokine or other secreted immune molecule.
Learn why the European Immunogenicity Platform (EIP) believes that a multidisciplinary approach is warranted to better understand and minimize drug immunogenicity.
With ELISpot, our scientific team is able to achieve the degree of sensitivity needed to accurately detect and enumerate rare antigen-specific cells and evaluate helper T cell response.
In fact, BioAgilytix’s ELISpot platform is qualified and validated for regulated studies involving biologics and gene therapies, and our team has a proven track record of leveraging this platform to deliver high-quality qualitative results.
Speak with one of our ELISpot experts about your scientific requirements, and we will discuss how the features of this platform can be optimally applied your assay requirements. ELISpot experts available in both our US and European labs.
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 858-652-4699
37 Kent St, Woolloongabba
Queensland, 4102, Australia
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 617-456-0700
37 Kent St,Woolloongabba
Queensland, 4102, Australia
1320 Soldiers Field Road
Boston, MA, 02135
1320 Soldiers Field Road
Boston, MA, 02135
617-456-0700
Fax 617-456-0701
Lademannbogen 10
22339 Hamburg Germany
+49 405267790
85 Commercial Road, Melbourne
Victoria, 3004, Australia
03 9282 2184
Lademannbogen 10
22339 Hamburg Germany
85 Commercial Road, Melbourne
Victoria, 3004, Australia
Copyright © 2022 BioAgilytix Labs.
All rights reserved.